CNY 14.2
(1.21%)
Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Operating Cash Flow | 83.08 Million | 23.08 Million | 7.63 Million | 6.98 Million | 66.53 Million | 53.66 Million |
Net Income | 50.33 Million | 44.95 Million | 35.51 Million | 67.59 Million | 80.76 Million | 73.05 Million |
Depreciation & Amortization | 8.26 Million | 8.25 Million | 7.06 Million | 3.57 Million | 3.32 Million | 2.8 Million |
Deferred income taxes | -1.65 Million | -2.39 Million | -2.13 Million | -929.55 Thousand | 587.25 Thousand | -908.1 Thousand |
Stock-based compensation | 10.17 Million | 2.39 Million | 2.13 Million | 929.55 Thousand | -587.25 Thousand | - |
Change in working capital | 20.67 Million | -40 Million | -42.58 Million | -72.55 Million | -20.66 Million | -25.37 Million |
Other non-cash items | 1.3 Million | 9.87 Million | 7.63 Million | 8.37 Million | 3.11 Million | 3.19 Million |
Investing Cash Flow | -116.3 Million | -45.72 Million | -43.73 Million | -68.97 Million | -8.96 Million | -23.47 Million |
Investments in PPE | -36.32 Million | -45.72 Million | -43.76 Million | -57.61 Million | -19.93 Million | -16.02 Million |
Acquisitions | 20.03 Thousand | - | 36 Thousand | 57.61 Million | 19.98 Million | - |
Investment purchases | -80 Million | - | - | -48.39 Million | -144.5 Million | -70.5 Million |
Sales/Maturities of investments | - | - | - | 37.02 Million | 155.41 Million | 63.04 Million |
Other Investing Activities | -79.97 Million | - | 36 Thousand | -57.61 Million | -19.93 Million | 0.23 |
Financing Cash Flow | -28.52 Million | -29.8 Million | -60.1 Million | 369.2 Million | -22.3 Million | 21.58 Million |
Debt repayment | -28 Million | -3 Million | -3.08 Million | -30 Million | - | - |
Dividends payments | -22.16 Million | -27.7 Million | -55.41 Million | - | -20.77 Million | -19.65 Million |
Common Stock Repurchased | - | - | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | 24.67 Million | 2.47 Million | -3.08 Million | 399.2 Million | -1.52 Million | 41.24 Million |
Accounts receivables | 10.27 Million | -17.8 Million | -24.71 Million | -55.07 Million | -42.3 Million | -25.2 Million |
Accounts payables | 29.75 Million | 15.56 Million | 7.78 Million | 13.69 Million | 21.67 Million | 12.88 Million |
Inventory | -19.34 Million | -35.37 Million | -23.52 Million | -30.25 Million | -620.84 Thousand | -12.15 Million |
Other working capital | 28.09 Million | -2.39 Million | -2.13 Million | -929.56 Thousand | 587.25 Thousand | -13.22 Million |
Cash at beginning of period | 385.56 Million | 409.22 Million | 505.43 Million | 198.21 Million | 162.95 Million | 111.17 Million |
Cash at end of period | 307.11 Million | 356.78 Million | 409.22 Million | 505.43 Million | 198.21 Million | 162.95 Million |
Capital Expenditure | -36.32 Million | -45.72 Million | -43.76 Million | -57.61 Million | -19.93 Million | -16.02 Million |
Effect of forex changes on cash | - | 0.05 | 0.24 | - | - | 1749.36 |
Net cash flow / Change in cash | -78.45 Million | -52.43 Million | -96.2 Million | 307.21 Million | 35.26 Million | 51.78 Million |
Free Cash Flow | 46.76 Million | -22.63 Million | -36.13 Million | -50.62 Million | 46.59 Million | 37.64 Million |
Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - |
Net Income | -1.14 Million | 14.83 Million | -4.79 Million | 44.44 Million | 50.33 Million | -3.23 Million |
Depreciation & Amortization | - | 2.77 Million | 2.77 Million | 2.2 Million | 8.26 Million | -3.84 Million |
Deferred income taxes | - | - | - | - | -1.65 Million | -22.32 Million |
Stock-based compensation | - | 2.45 Million | - | 10.17 Million | 10.17 Million | -7.1 Million |
Change in working capital | - | 46.55 Million | - | -9.07 Million | 20.67 Million | 33.28 Million |
Other non-cash items | -3.16 Million | 4.22 Million | -32.32 Million | 98.78 Million | 1.3 Million | 25.04 Million |
Investing Cash Flow | -22.07 Million | -29.36 Million | -6.44 Million | -85.82 Million | -116.3 Million | -10.38 Million |
Investments in PPE | -41.76 Million | -9.36 Million | -6.44 Million | -5.84 Million | -36.32 Million | -10.38 Million |
Acquisitions | - | - | - | 17.24 Thousand | 20.03 Thousand | 2783.00 |
Investment purchases | - | -20 Million | - | -80 Million | -80 Million | - |
Sales/Maturities of investments | 20 Million | - | - | - | - | - |
Other Investing Activities | -304.33 Thousand | -20 Million | - | -79.98 Million | -79.97 Million | 2783.00 |
Financing Cash Flow | -1.55 Million | -23.54 Million | -20.31 Million | -21.1 Million | -28.52 Million | -19.23 Million |
Debt repayment | -2 Million | -1.8 Million | -200 Thousand | -24 Million | -28 Million | -2.93 Million |
Dividends payments | - | -26.01 Million | -21.06 Thousand | -22.16 Million | -22.16 Million | -23.5 Million |
Common Stock Repurchased | - | -20.09 Million | - | - | - | - |
Common Stock Issuance | - | - | - | - | - | - |
Other Financing Activities | 449.16 Thousand | -1.64 Million | -20.11 Million | 28.1 Million | 24.67 Million | 7.2 Million |
Accounts receivables | - | 44.54 Million | - | 10.27 Million | 10.27 Million | 34.46 Million |
Accounts payables | - | - | - | - | 29.75 Million | - |
Inventory | - | 2.01 Million | - | -19.34 Million | -19.34 Million | -1.18 Million |
Other working capital | - | - | - | - | - | - |
Cash at beginning of period | 198.05 Million | 234.67 Million | 307.11 Million | 281.37 Million | 385.56 Million | 268.74 Million |
Cash at end of period | 206.02 Million | 198.05 Million | 234.67 Million | 307.11 Million | 307.11 Million | 260.93 Million |
Capital Expenditure | -41.76 Million | -9.36 Million | -6.44 Million | -5.84 Million | -36.32 Million | -10.38 Million |
Effect of forex changes on cash | - | - | - | - | - | 0.86 |
Net cash flow / Change in cash | 7.97 Million | -36.62 Million | -72.43 Million | 25.73 Million | -78.45 Million | -7.81 Million |
Free Cash Flow | -46.08 Million | 6.92 Million | -43.57 Million | 135.18 Million | 46.76 Million | 11.42 Million |
603367
JMT
NCI
300081
SYNE3
000983